STOCK TITAN

Zai Lab (ZLAB) insider files Form 144 to sell 3,000 ADS valued $105K

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

What: Form 144 notice related to Zai Lab Limited (ZLAB) reporting a proposed sale of American Depositary Shares (ADS).

Key facts:

  • Shares to be sold: 3,000 ADS
  • Aggregate market value: $105,000.00
  • Approximate sale date: 08/08/2025
  • Exchange: NASDAQ
  • Shares outstanding (issuer): 421,725,450

Acquisition: ADS were acquired on 12/30/2023 via restricted stock vesting from the issuer; consideration/ payment listed as compensation.

Other: The filing states "Nothing to Report" for securities sold in the past three months. Some filer/contact fields in the form content are not populated.

Positive

  • Regulatory compliance: Filing provides required Rule 144 details including acquisition date, nature (restricted stock vesting), and intended sale date
  • Clear transaction data: Specifies 3,000 ADS, $105,000.00 aggregate market value, and exchange (NASDAQ)

Negative

  • Insider disposition: Proposed sale by a person for whose account the securities are to be sold is disclosed
  • Incomplete contact fields: Submission contact and some issuer/filer fields in the provided content appear unpopulated

Insights

TL;DR: Form 144 discloses a proposed sale of 3,000 ADS (aggregate $105,000) scheduled for 08/08/2025; acquisition was restricted stock vesting.

The filing documents a single proposed sale of 3,000 ADS with an aggregate market value of $105,000.00, scheduled for 08/08/2025 on NASDAQ. The ADS were acquired on 12/30/2023 as restricted stock vesting and the payment/consideration is recorded as compensation. The form notes "Nothing to Report" for sales in the prior three months. The disclosure meets Rule 144 reporting requirements by providing acquisition and intended-sale details.

TL;DR: Routine insider disclosure: proposed sale documented with acquisition details; limited additional context or contact data in the provided form content.

The notice specifies the nature of acquisition (restricted stock vesting) and the intended disposition date. The filing indicates no related sales in the prior three months. Within the provided content, several contact and issuer-identifying fields are not populated, which reduces on-form transparency. The document is a routine compliance disclosure rather than a material corporate event in the filing as presented.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for Zai Lab (ZLAB) report?

The filing reports a proposed sale of 3,000 ADS with an aggregate market value of $105,000.00.

When is the proposed sale scheduled for ZLAB Form 144?

The approximate date of sale listed is 08/08/2025.

How were the ADS acquired according to the filing?

The ADS were acquired on 12/30/2023 via restricted stock vesting; the consideration is listed as compensation.

Were there any securities sold in the past three months by the seller?

The filing states "Nothing to Report" for securities sold during the past three months.

On which exchange will the proposed sale be effected?

The filing lists the securities exchange as NASDAQ.
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Latest SEC Filings

ZLAB Stock Data

2.09B
106.96M
1.74%
42.53%
4.26%
Biotechnology
Pharmaceutical Preparations
Link
China
SHANGHAI